机构地区:[1]重庆市大足区人民医院泌尿外科,重庆402360
出 处:《中国医院用药评价与分析》2022年第10期1216-1219,共4页Evaluation and Analysis of Drug-use in Hospitals of China
基 金:重庆市大足区科技计划项目(No.DZKJ,2019ACC1022)。
摘 要:目的:观察还少胶囊联合盐酸坦索罗辛治疗脾肾阳虚型早泄的临床效果。方法:选取2019年6月至2020年5月该院收治的脾肾阳虚型早泄患者120例,按随机数字表法分成盐酸坦索罗辛组、还少胶囊组和联合组,每组40例。盐酸坦索罗辛组患者给予盐酸坦索罗辛治疗,1次0.2 mg, 1日1次;还少胶囊组患者给予还少胶囊治疗,1次5粒,1日2次;联合组患者给予还少胶囊联合盐酸坦索罗辛治疗,均治疗30 d。比较三组患者的疗效、射精潜伏时间(IELT)、中国早泄患者性功能指数(CIPE)、不良反应发生率和夫妻双方性生活满意度。结果:联合组患者的总有效率为90.00%(36/40),明显高于盐酸坦索罗辛组的67.50%(27/40)、还少胶囊组的70.00%(28/40),差异均有统计学意义(P<0.05)。治疗后,三组患者的IELT长于治疗前,CIPE高于治疗前,差异均有统计学意义(P<0.05);联合组患者的IELT明显长于盐酸坦索罗辛组、还少胶囊组,CIPE明显高于盐酸坦索罗辛组、还少胶囊组,差异均有统计学意义(P<0.05)。联合组、还少胶囊组患者的不良反应发生率分别为2.50%(1/40)、0(0/40),低于盐酸坦索罗辛组的20.00%(8/40),差异均有统计学意义(P<0.05)。联合组患者的满意度为90.00%(36/40),明显高于盐酸坦索罗辛组的62.50%(25/40)、还少胶囊组的67.50%(27/40),差异均有统计学意义(P<0.05)。结论:还少胶囊联合盐酸坦索罗辛治疗脾肾阳虚型早泄的疗效较好,能延长IELT,改善CIPE,提高夫妻双方性生活满意度,且不良反应少。OBJECTIVE: To probe into the clinical effects of Huanshao capsules combined with tamsulosin hydrochloride in the treatment of premature ejaculation of spleen and kidney yang deficiency type. METHODS: Totally 120 patients with premature ejaculation of spleen and kidney yang deficiency type admitted into the hospital from Jun. 2019 to May 2020 were extracted to be divided into the tamsulosin hydrochloride group, Huanshao capsules group and combination group via the random number table method, with 40 cases in each group. Tamsulosin hydrochloride group was treated with tamsulosin hydrochloride, 0.2 mg for once, qd. Huanshao capsules group received Huanshao capsules, 5 capsules for once, bid. Combination group was given Huanshao capsule combined with tamsulosin hydrochloride, for 30 d. The efficacy, intravaginal ejaculation latency time(IELT), Chinese index of sexual function for premature ejaculation(CIPE), incidence of adverse reactions and sexual satisfaction of both spouses were compared among three groups. RESULTS: The total effective rate of the combination group was 90.00%(36/40), significantly higher than 67.50%(27/40) of the tamsulosin hydrochloride group and 70.00%(28/40) of the Huanshao capsules group, the differences were statistically significant(P<0.05). After treatment, the IELT of three groups was longer than that before treatment, and the CIPE was higher than that before treatment, the differences were statistically significant(P<0.05);the IELT of the combination group was significantly longer than that of the tamsulosin hydrochloride group and the Huanshao capsules group, and the CIPE of the combination group was significantly higher than that of the tamsulosin hydrochloride group and the Huanshao capsules group, the differences were statistically significant(P<0.05). The incidence of adverse drug reactions in the combination group and Huanshao capsules group were respectively 2.50%(1/40) and 0(0/40), lower than 20.00%(8/40) in the tamsulosin hydrochloride group, the differences were statistically s
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...